3-(1-methyl-1H-pyrazol-4-yl)-N-(3-(4-(methylcarbamoyl)-3-(trifluoromethyl)phenyl)-6-oxopyridazin-1(6H)-yl)quinoline-6-carboxamide

ID: ALA5176316

Chembl Id: CHEMBL5176316

PubChem CID: 168276157

Max Phase: Preclinical

Molecular Formula: C27H20F3N7O3

Molecular Weight: 547.50

Associated Items:

Names and Identifiers

Canonical SMILES:  CNC(=O)c1ccc(-c2ccc(=O)n(NC(=O)c3ccc4ncc(-c5cnn(C)c5)cc4c3)n2)cc1C(F)(F)F

Standard InChI:  InChI=1S/C27H20F3N7O3/c1-31-26(40)20-5-3-15(11-21(20)27(28,29)30)23-7-8-24(38)37(34-23)35-25(39)16-4-6-22-17(9-16)10-18(12-32-22)19-13-33-36(2)14-19/h3-14H,1-2H3,(H,31,40)(H,35,39)

Standard InChI Key:  XGLIFFAKDVMFLE-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA5176316

    ---

Associated Targets(Human)

MET Tclin Hepatocyte growth factor receptor (10718 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hs746T (53 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 547.50Molecular Weight (Monoisotopic): 547.1580AlogP: 3.62#Rotatable Bonds: 5
Polar Surface Area: 123.80Molecular Species: NEUTRALHBA: 8HBD: 2
#RO5 Violations: 1HBA (Lipinski): 10HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
CX Acidic pKa: 9.11CX Basic pKa: 3.39CX LogP: 2.81CX LogD: 2.80
Aromatic Rings: 5Heavy Atoms: 40QED Weighted: 0.35Np Likeness Score: -1.56

References

1. Wang C, Li J, Qu L, Tang X, Song X, Yang F, Chen X, Lin Q, Lin W, Zhou Y, Tu Z, Chen Y, Zhang Z, Lu X..  (2022)  Discovery of D6808, a Highly Selective and Potent Macrocyclic c-Met Inhibitor for Gastric Cancer Harboring MET Gene Alteration Treatment.,  65  (22.0): [PMID:36355693] [10.1021/acs.jmedchem.2c00981]

Source